Company Encyclopedia
View More
name
Alpha Tau Medical
DRTS.US
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
1.380 T
DRTS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers

    Biotech stocks rebounded in after-hours trading following steep regular-session losses. Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways led the gains, driven by clinical data, FDA designations, and financing announcements. Stoke Therapeutics rose 11.42%, Alpha Tau Medical surged 25.26%, and Compass Pathways climbed 4.40%. Other notable movers included Absci Corp, Senti Biosciences, TuHURA Biosciences, and Maravai LifeSciences Holdings.

    rttnews·
    US
    DRTS
    +1.81%
    US
    CMPS
    -2.88%
    US
    STOK
    -2.12%
    rttnews·
    US
    DRTS
    +1.81%
    US
    CMPS
    -2.88%
    US
    STOK
    -2.12%

    Alpha Tau Medical Treats First Glioblastoma Patient with Alpha DaRT in U.S. Trial

    Alpha Tau Medical Ltd. successfully treated the first glioblastoma patient using Alpha DaRT technology in a U.S. trial at The James Cancer Hospital. This marks the first use of Alpha DaRT for brain cancer, part of Alpha Tau's strategy to address unmet cancer treatment needs. Results are pending.

    Reuters·
    US
    DRTS
    +1.81%
    Reuters·
    US
    DRTS
    +1.81%

    Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer

    Alpha Tau Medical Ltd. has initiated a multi-center clinical trial in the U.S. to evaluate its Alpha DaRT® alpha-radiation cancer therapy for newly diagnosed pancreatic cancer. The trial began in September 2025 and aims to enroll 30 participants by Q1 2026. Two related abstracts will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. Results from a pilot trial in Montreal will also be presented.

    Reuters·
    US
    DRTS
    +1.81%
    Reuters·
    US
    DRTS
    +1.81%

    H.C. Wainwright Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)

    H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Alpha Tau Medical Ltd with a price target of $9.00. Piper Sandler also reiterated a Buy rating with a $5.00 price target.

    Tip Ranks·
    US
    DRTS
    +1.81%
    Tip Ranks·
    US
    DRTS
    +1.81%

    Alpha Tau Medical Wins FDA Approval to Begin Prostate Cancer Trial

    Alpha Tau Medical Ltd. has received FDA approval to start a pilot study of its Alpha DaRT technology for treating locally recurrent prostate cancer. This is the company's fifth active IDE in the U.S. The trial will involve up to 12 patients, focusing on safety and assessing efficacy through disease progression and survival measures. The news was published by Alpha Tau Medical via GlobeNewswire on December 2, 2025.

    Reuters·
    US
    DRTS
    +1.81%
    Reuters·
    US
    DRTS
    +1.81%
    © 2025 Longbridge｜Disclaimer